Northwire Canada EditionSunday, July 12, 2026
Northwire
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
M&A / Property

Tilray Expands UK Pharmaceutical Access Through Strategic Agreement with Smartway Pharmaceuticals

TLRY · Price

Executive Summary

  • Tilray Pharma’s European distribution arm, CC Pharma, entered a strategic agreement with UK‑based Smartway Pharmaceuticals to expand parallel import and specialist pharmaceutical supply in the United Kingdom.
  • The partnership leverages Smartway’s national distribution network and CC Pharma’s procurement and GMP capabilities, targeting the roughly £1 billion UK market for these product categories.
  • Both parties will explore further collaborative opportunities, reinforcing Tilray’s broader European medical expansion strategy and positioning its medicinal cannabis products within the UK health system.

Key Details

  • Agreement Scope: Joint support of parallel import and specialist pharmaceutical supply across the UK; combined use of Smartway’s distribution infrastructure and CC Pharma’s procurement/GMP capacity.
  • Market Opportunity: UK market for these pharmaceutical categories estimated at ~£1 billion.
  • Strategic Rationale: Enhances Tilray’s ability to broaden access to medicinal products, improve supply reliability, and embed its cannabis medicines into the UK health system.
  • Relationship History: CC Pharma and Smartway have collaborated since 2009; this agreement represents the next phase of that partnership.
  • Future Collaboration: Both companies will assess additional opportunities for broader cooperation over time.

Notable Quotes

  • “The UK is a priority market within Tilray’s international medical strategy…this agreement strengthens our ability to broaden access to medicinal products…” – Rajnish Ohri, President, International, Tilray Brands.
  • “This agreement represents an important step forward in expanding our pharmaceutical distribution activities into the UK.” – Mathias Bossen, Managing Director, CC Pharma.
  • “Our focus is always on patients and outcomes…this agreement supports continuity and expansion of access to medicines across UK healthcare.” – Josh Cocklin, Chief Executive, Smartway Pharmaceuticals.
Read the original news release →

More from TILRAY BRANDS, INC. J